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1. Abstract 
 
BRONJ is a serious oral complication of BP treatment involving the exposure of necrotic maxillary or mandibular bone. 
We investigated the pathogenetic hypothesis and new preventive measures for BRONJ in patients with bone metastases 
who received BP zoledronic acid (ZOL) and chemotherapy combined with the antiangiogenic agent bevacizumab 
(BEV). 
The pathogenesis of BRONJ is uncertain: the type of BP, duration of the drug use and the occurrence of tooth 
extractions or other invasive dental procedures during treatment seem to play a major role. A theory that BRONJ is a 
form of avascular necrosis similar to osteoradio-necrosis also has been proposed. It maybe hypothesized that the 
combination of the antiangiogenic agent BEV with ZOL can lead to the enhancement of bone tissue avascularization 
(reduction of vascularization), which can account for a potentially higher incidence of ONJ in patients with bone 
metastases [to the bone] who receive this type of treatment.In order to better understand the problem we followed up a 
total of 121 patients for a period of 3 years. 
 Methods: Patients were divided into 2 groups: group PA (preventive approach, 78 patients) and group OB 
(observation, 63 patients). Group PA patients had never been previously treated with BP, and group OB patients had 
already undergone therapy with BP. All patients received a complete oral and dental examination and a panoramic 
radiograph. If necessary, oral hygiene, restorative and rehabilitation therapy were offered to patients. All patients 
participated in regular checkups every 3 months. Group PA patients underwent oral surgical procedures, as needed. 
Group OB patients underwent less invasive procedures (restorative treatment) or root canal and surgical procedures, as 
needed. 
Results:In group OB is interesting to note that the 16 patients with root canal treatment have not developed BRONJ, 
suggesting that a mini invasive procedure is highly reccomended for patients who have already stareted ZOL + BEV, 
while 14% of patients, who underwent oral surgical procedures,  presented with BRONJ during the 18 month follow up 
period. No patients in group PA had ONJ.  
Conclusion: Current evidence suggests that root canal therapy in cancer patients is a safe procedure and may reduce the 
incidence of ONJ. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2. Introduction 
 
Bisphosphonates (also called diphosphonates) are a class of drugs that prevent the loss of bone mass. They are called 
bisphosphonates because they have two phosphonate (PO3) groups and are similar in structure to pyrophosphate. 
Bisphosphonates are the main drugs used for sckeletal helth preservation and treatment of osteoporosis, osteitis 
deformans ("Paget's disease of bone"), bone metastasis (with or without hypercalcaemia), multiple myeloma, primary 
hyperparathyroidism, osteogenesis imperfecta, and other conditions that feature bone fragility(1). 
 
This class of drug has been classified into 2 groups, non-nitrogen-containing bisphosphonates (etidronate and 
clodronate) and nitrogen-containing bisphosphonates (pamidronate, risedronate, alendronate, and zoledronate)(2). In 
oncology, nitrogen-containing bisphosphonates have been used widely to manage hypercalcemia related to malignancy 
and bone metastases (3,4,5). 
 
 
Bisphosphonates were originally synthesized in 1865 their Germany (6), and due to their ability to inhibit calcium 
carbonate precipitation, first  use was in the textile, fertilizer and oil industries as preventers of scaling (7). 
 
Etidronate, the first bisphosphonate  used to treat a human disease (8), was synthesized 100 yr ago. Their ability to 
inhibit calcium carbonate precipitation, similar to polyphosphates, was  used in the prevention of scaling . Only in the 
past three decades bisphosphonates have been developed as drugs for use in various diseases of bone, tooth, and 
calcium metabolism. 
 
Mechanisms of Action of BF 
 
Many studies using a variety of experimental systems showed that bisphosphonates inhibit osteoclast-mediated bone 
resorption, not only in “in vitro” bone-cells cultures, but also in “in vivo” animals, both in normal ones and in those 
with experimentally increased bone resorption (9).  
 
cellular effects 
 
Bisphosphonates are recognized as inhibiting osteoclastic activity by four main processes: 
1) Induction of osteoclastic apoptosis, 
2) inhibition of osteoclastic resorption of bone, 
3) inhibition of osteoclastic maturation, 
4) inhibition of osteoclastic recruitment.  
 
Apart from these effects on osteoclasts, bisphosphonates have also been shown to have effects on angiogenesis 
epithelial cells growth . 
Angiogenesis plays a fundamental role in normal physiologic processes, such as organogenesis during embryonic 
development, tissue remodeling/maintenance healing throughout life, and reproductive functions(10,11). Compensatory 
angiogenesis is also required in the formation of collateral blood vessels in the setting of hypoxia and nutrient 
deprivation (11,12). Angiogenesis is essential in neoplasia and the vascular endothelial growth factor (VEGF) is 
produced and secreted by a number of neoplastic cells.  In effect, the initiating event in the angiogenetic process is the 
release of proangiogenic growth factors, such as VEGF, fibroblast growth factor (FGF) or plateled-derived growth 
factor (PDGF) from diseased or injured cells (14,15) There are a variety of stimuli mediating the release of these growth 
factors – hypoxia, hypoglycemia, mechanical stress, secreted proteins in the microenvironment, inflammatory factors 
and genetic alterations. 
Endothelial cell proliferation, adhesion and migration are inhibited by zoledronic acid in vitro (16). Both nitrogen and 
non-nitrogen containing bisphosphonates have been demonstrated to inhibit revascularization of tissue in vivo and 
angiogenesis (17,18) 
Pamidronate has even been demonstrated to have a direct apoptotic effect on certain myeloma cell lines (19). 
 
Clinical applications of BF 
 
Bisphosphonate medications are currently prescribed for the treatment of osteoporosis, Paget’s disease, bone metastases 
.Bisphosphonates are also effective in reducing the risk of skeletal-related events in persons with metastatic breast, lung, 
and prostate cancer as well as multiple myeloma – affecting a range of complications that include malignant severe 
hypercalcaemic episodes, new bone metastases, diffuse bone pain and pathologic fracture (20). They have also found 
off-label use in a number of bone-affecting diseases such as osteogenesis imperfecta (21,22). 
 
The Epidemiology of BRONJ 
 
The precise epidemiological features of BRONJ have not been determined.  
In the general population amongst patients not receiving bisphosphonates as a treatment for cancer, Felsenberg reported 
an incidence of 0.00038% (23).  
The American Society for Bone and Mineral Research taskforce in 2007 estimated the incidence, based on publications 
and pharmaceutical company reports, to be between 1 and 10% of patients taking intravenous bisphosphonates for the 
treatment of cancer and less than 1% in patients with osteoporosis or Paget’s disease (24). 
 
Current incidence data for BRONJ are limited to retrospective studies with limited sample sizes. The current difficulty 
in establishing exact incidence data stems from several factors, including a nonstandardized definition and 
inconsistencies in case recognition and reporting. With that understanding, the estimate of cumulative incidence of 
BRONJ in patients receiving intravenous bisphosphonates for malignant disease ranges from 0.8% to 12%(25) For 
those patients exposed to oral bisphosphonates, the incidence appears to be significantly less(25).  
 
Risk factors 
 
Several retrospective clinical studies have identified potential risk factors associated with the development of 
BRONJ.(26,27) These include a history of dentoalveolar trauma, duration of bisphosphonate exposure, and the type of 
bisphosphonate. In the majority of BRONJ cases reported to date, recent dentoalveolar trauma was the most prevalent 
and consistent risk factor.(26,28,29) Patients with a history of inflammatory dental disease (e.g., periodontal and dental 
abscesses) are at a sevenfold increased risk for developing BRONJ.(30) In a case series, the use of chronic steroids in 
conjunction with bisphosphonates has also been identified as a potential risk factor.(25)  
Patients receiving oral bisphosphonate therapy for osteoporosis that develop BRONJ have typically been exposed to 
these agents for a longer period of time (greater than 3 years) or were also exposed to steroid therapy.(25,31) 
 
Aetio-pathogenesis of BRONJ  
 
The precise aetiological mechanism behind the development of bisphosphonate-related osteonecrosis has not been 
determined. Epidemiological correlations have been observed, however, and a number of theories have been proposed. 
 
 Bisphosphonate Potency  
 
To date, the most important predisposing factors identified for the development of bisphosphonate-associated 
osteonecrosis of the jaws are the type and total dose of bisphosphonate and the history of trauma, dental surgery or 
dental infection (27). BRONJ has been associated most often with the nitrogen containing bisphosphonates, specifically 
pamidronate and zolendronate (5,32,33). It is not currently understood by what specific mechanism nitrogen containing 
bisphosphonates induce a higher risk of BRONJ development than their non-nitrogen containing counterparts. The 
increased potency of nitrogen containing bisphosphonates over non-nitrogen containing bisphosphonates is, however, 
well recognized (34). Patients receiving bisphosphonates intravenously have been demonstrated to be more susceptible 
to BRONJ than those receiving the drug orally (35).  
 
 Bisphosphonate Inhibition of Bone Remodeling 
 
The prevailing hypothesis focuses on a drug-induced defect in jawbone physiologic remodeling 
or wound healing. The profound inhibition of osteoclast function inhibits normal bone turnover 
to an extent that local micro damage from normalmechanical loading or injury (tooth extraction) 
cannot be repaired.(36) This can ultimately results in bone necrosis. The recent reports of jaw necrosis in patients 
receiving DenosumabR _ , a monoclonal antibody that targets osteoclasts by a completely different mechanism than 
bisphosphonates, supports the hypothesis osteoclast inhibition might be the primary event in the pathogenesis of this 
complication. (37,38) 
 
 Direct Tissue Toxicity 
 
Other studies have focused on the soft tissue response and demonstrated that bisphosphonates can be directly toxic to 
the oral mucosa, which may result in mucosal fenestration and bone exposure(39). It is possible bisphosphonates are 
accumulated in bone in concentrations sufficient to be directly toxic to the oral epithelium, resulting in the failure of 
healing of soft tissue lesions (40). Bisphosphonates at a high enough concentration have a demonstrable toxic effect, 
both in animal models (41) and in in vivo studies (42).  
Because only a minority of bisphosphonate users develop bone necrosis, it is also possible that individual genetic 
variations in drug metabolism or skeletal homeostasis may confer susceptibility or resistance to developing BRONJ 
(43). These theories and suppositions need to be validated by evidence-basedclinical and basic science research. 
 
 Influence of Medical Co-Morbidities  
 
The impact of local factors such as smoking, and of underlying medical conditions such as peripheral vascular diseases 
remains to be determined. There is some evidence and a theoretical justification for a correlation between diabetes 
mellitus and BRONJ (44), however more research is required in this area. 
 
 Influence of Anatomy 
 
The apparent selective involvement of the maxilla and mandible may be a reflection of the unique 
environment of the oral cavity. Typically, healing of an open bone wound (e.g., extraction socket) in the presence of 
normal oral microflora occurs quickly andwithout complication. However, when the healing potential of the mandible 
or maxilla is compromised either by tumorcidal radiation doses or some other agent(s) or pathologic process, then 
minor injury or disease in these sites increases the risk for osteonecrosis and possible secondary osteomyelitis. 
Also, bisphosphonates are preferentially deposited in bones with high turnover rates; given that the 
maxilla and mandible are sites of significant bone remodeling, it is possible that the levels of bisphosphonate within the 
jaw are selectively elevated. It is interesting to note that to date this complication of bisphosphonate-related bone 
necrosis has not been reported within bones outside the craniofacial skeleton.(31) 
 
 Genetic Predisposition to BRONJ  
 
A genetic predisposition to developing BRONJ has been suggested. The rs1934951 polymorphism mapped within 
cytochrome P450-2C polypeptide 8 gene may be associated with increased risk for the development of BRONJ in 
myeloma patients who receive intravenous bisphosphonates (43). 
 
Staging of BRONJ 
 
Staging of a disease allows for grouping of similar patients to compare outcomes and results of treatments, and the same 
holds true for BONJ where several different staging systems have been proposed, but the simple clinically-based 
staging system proposed by Ruggiero et al has been the most widely accepted and used in most publications and 
guidelines on BRONJ(45) This was revised in the AAOMS position paper in 2009 (Table 2)(25). 
 
 
 
Table 2  Staging of Bisphosphonate Related Osteonecrosis of the Jaws. Based on recommendations of the 
American Association of Oral & Maxillofacial Surgeons 
 
Stage Clinical features 
Stage 0 No apparent exposed/necrotic bone (but who present with signs and/or 
symptoms suggestive of future disease) 
Stage 1 Exposed/Necrotic bone in asymptomatic patient with no evidence on 
infection 
Stage 2 Exposed/Necrotic bone associated with localised infection 
Stage 3 Exposed/Necrotic bone associated with pathological fracture, extra-oral 
fistula or extension in to surrounding basal bone 
 
 
 
Management of BRONJ 
 
The aims of treating patients with BRONJ are to eliminate clinical symptoms such as pain, treat any infection of the soft 
tissues or bone, and minimise the progression of bone necrosis.(88) Clinical markers of success include an intact 
mucosa with no signs of infection or sinus formation and radiographic markers include the arrest of progression of the 
bony abnormality or remodelling of the affected area.(46) 
 
Surgical management 
 
The goal of surgical treatment is to remove necrotic bone and create soft tissue coverage of remaining healthy bone. 
The difficulty with this approach is knowing how much bone removal is sufficient because as BP are administered 
systemically and affect the whole bony skeleton, there is effectively no unaffected bone.(47,48,49) 
The most commonly recommended approach is to remove symptomatic bony sequestra with minimal soft tissue 
disturbance and avoiding further bone exposure, although some authors advocate more extensive soft and hard tissue 
debridement and primary closure of the wound.(47,50) 
More radical surgical management is advocated where there are large segments of necrotic bone or where there is 
pathological fracture of the bone (AAOMS stage 3).(47,25) 
En bloc resection of alveolar and basal bone of the maxilla and mandible can then be reconstructed with a combination 
of local or regional flaps or vascularised or non-vascularised free flaps. In the maxilla an oral-nasal or oral-antral 
communication may be managed with an obturator.(25,51,52) 
 
Non-surgical management 
 
The use of antiseptic mouthwashes (chlorhexidine gluconate or hydrogen peroxide) and/or analgesia is proposed for 
patients with clinical evidence of BRONJ (such as exposed bone) but in the absence of any evidence of infection 
(AAOMS Stage 1).(47,25) It is essentially a strategy to reduce the likelihood of further progression of BONJ and avoid 
infection of exposed bone.(28)  
 
Where there is evidence of local inflammation or infection, antibiotics are advised.(47,53) Broad spectrum 
antimicrobial therapy (phenoxymethylpenicillin, amoxicillin or coamoxiclav or clindamycin _ metronidazole) is 
recommended although the correct duration of treatment is not clear.(47,53,54) This approach is indicated for patients 
generally categorised as stage 2 BRONJ, but it may also be the preferred approach in patients with BRONJ and cancer 
with very poor prognosis in whom more extensive treatment is not indicated.(47,25,54) 
 
Adjunctive therapies  
 
They include hyperbaric oxygen (HBO), parathyroid hormone, platelet rich plasma, lasers and local application of O3. 
With the exception of HBO, the literature consists primarily of small case series and further studies need to be 
undertaken before any are considered for routine use.(25) 
HBO had very limited effects (32,28). Later studies did seem to indicate a beneficial effect of HBO as supportive 
therapy (55,56). 
New and original therapeutic approach for the clinical management of small necrotic maxillary lesions in ONJ was 
based on a non-surgical intervention for the application of O3. This approach consisted of in situ positioned O3 oil 
suspension to increase the therapeutic effect of O3 and to reduce the risk of infection or inspiration in the oral cavity. 
Consequently, this approach showed a 
good safety profile. Antimicrobial treatment before starting the O3 oil applications plays a critical role in reducing the 
severity of inflammation and infection The results demonstrate that medical O3 delivered in an oil suspension should be 
considered a promising, effective, safe and simple therapeutic option for the treatment of small ONJ lesions(57) 
                                                           CLINICAL STUDY 
 
 
3. Aims 
 
The aim of the present study was to evaluate the effectiveness of preventive strategies in 121 patients who underwent 
therapy with BPs at the department of dentistry in Siena Hospital 
 
The results were hoped to aid in gauging the scope of the impact that bisphosphonates may potentially have on the 
delivery of dental care to the general community 
 
 
4. Materials and Methods 
 
Patients were referred from the Department of Oncology to the Department of Dentistry, from January 2008 to July 
2010, to undergo dental evaluation and receive necessary treatment before initiating therapy with zoledronate. 
 
Eligibility criteria 
 
The study involved patients with measurable or evaluable istologically confirmed solid tumors that received BP and 
bevacizumab combined with chemotherapy, not previously included in a preventive dental program (basal dental 
examination, OPT and preventive dental care), age 18-75 years,  ECOG P.S. of 0-2, bidimensionally measurable 
disease, a life expectancy of at least 3 months, an absolute neutrophil count of ≥ 1.5 X 109 l-1 and platelet count of ≥ 100 
X 10
9
 l
-1
 and creatininine and total bilirubin levels ≤ 1,25 times the upper normal limit. All patients should have 
received iv BP and bevacizumab for at least 3 months. The main baseline characteristics of all partecipants who 
received zoledronic acid every three months for almost one year or more are listed in Table 1.   The exclusion criteria 
were operable metastatic disease, severe cardiac dysfunction, chronic diarrhoea or incontrolled infection. The study was 
approved by our local ethic and scientific committee. 
 
 Table 1 
 
Characteristics Patients (N°) Patients who received 
zoledronic acid every 28 
days for almost one year 
(N°) 
Patients who received 
zoledronic acid  every 28 
days for more than one 
time per year (N°) 
Total  121 55 66 
Median Age (years-range) 60 (45-72)   
N° of Bone Lesions 
>3 
< 3 
 
74 
47 
 
36 
19 
 
38 
28 
Sex  
Male 
Female  
 
64 
57 
 
35 
27 
 
29 
30 
Primary Cancer   
Breast 
Non small cell lung 
Prostate  
 
41 
60 
20 
 
 
 
 
Received BEV more than six 
months  
92 
 
43 
 
49 
 
 
 
Patients evaluation  
 
All patients in the study provided written informed consent before the interview and visit. Information about their 
demographic characteristics, smoking habits, lifetime alcohol consumption and health history was collected. 
The evaluation, performed before study entry, included a detailed history and physical examination, a complete blood 
cell count with differential and platelet counts, whole-blood chemistry, and computed tomography (CT) scans and/or 
magnetic resonance imaging (MRI) of the chest and abdomen. During treatment, a complete blood cell count with 
differential and platelet counts was performed every 2 weeks. In addition, the patients were clinically assessed every 2 
weeks, and routine biochemical tests were performed. Imaging studies were performed prior to starting study and every 
6 months after the initiation of treatment or earlier when there was clinical deterioration, and response was evaluated 
according to RECIST criteria (version 2.0) (58). 
  
We evaluated a total of 121 patients that started BP and bevacizumab, and were examined by our Dental Care Unit at 
the first clinical visit at Oncology Department. For each patient, a dental examination and a Panoramic Radiographs 
were obtained at the first clinical visit and a dental examination was performed every month until patientes, died or lost 
to follow-up. The criteria we used to diagnose BRONJ included an exposed necrotic bone in the mandible or maxilla 
(associated or not associated with pain, soft-tissue swelling or purulent discharge) 
 
Patients were divided into 2 groups according to their BP history: group PA (preventive approach) or group OB 
(observation). Patients in group PA had never been previously treated with BP, whereas patients in group OB had 
already undergone therapy with BP. Patients in group PA received a clinical oral examination with visual inspection 
and palpation of the neck node regions, inspection of the oral and pharyngeal mucosa, periodontal examination and 
caries assessment. Finally, a panoramic radiograph was done to identify any radiographic anomalies. 
On the same day, patients were informed about the possible risk of BRONJ. Dental risks factors (59) were identified: 
presence of dental plaque and calculus; caries; dental infection, including periapical lesions and periodontal disease; 
periodontally compromised teeth (pocket depth ≥ 5 mm, clinical attachment level > 50%, mobility II and III, furcation); 
or poorly fitting dentures.(25) In the following days, all patients were treated to remove dental risk factors. Professional 
oral hygiene was done on the second visit; restorative and surgical procedures were done in the following visits. Oral 
surgery was aimed to prevent or treat bone infections; patients were advised about the risks of the surgical treatment. 
Finally, patients’ teeth were rehabilitated and oral hygiene instructions were given. 
Patients in group OB visited the dental clinic and had a panoramic radiograph. Dental risk factors 
were identified and patients were informed of the possible risk of BRONJ. If necessary, dental 
hygiene with antibiotic therapy, rehabilitation therapy, restorative and root canal treatment or dental extraction were 
offered to patients. 
 
Patients in both groups participated in regular checkups every 3 months, during which oral hygiene instructions were 
given again and patients were motivated to maintain good oral hygiene. 
Patients were instructed to report any swelling, pain or exposed bone. Overall, patients were followed for more than 18 
months. 
 
 
5. Results 
 
A total of 121 patients with bone metastases from different solid tumours were examined. The median age was 60 
(range 45-72) years, 55 received zoledronic acid every 28 days for almost one year and 66 received zoledronic acid 
every 28 days for more than one time per year, the primitive tumor was a breast cancer for 51 patients and 70 for 
NSCLC.  92 patients received BEV for more of six months (43 of those received zoledronic acid every 28 days for 
almost one year and 49 zoledronic acid every 28 days for more than one time per year); 47 patients presented less of 
three bone lesions (19 received zoledronic acid every 28 days for almost one year and 28 received zoledronic acid every 
28 days for more than one time per year). The median time the patients received zoledronic acid therapy was 16.7 
months (range 4.1-24.3 months); 77 patients had received zoledronic acid for more than one year. The median time 
partecipants received BEV was 13.4 months (range 3.8-26.6 months).  
 
Table 2. depicts dental risk factors for ONJ and associated comorbidities in our study population: 88 patients presented 
diabetes mellitus, 6 patients presented rheumatoid arthritis, 51 patients presented osteoarthritis and 20 patients presented 
osteoporosis. 
 
Table 2. Putative dental risk factors for ONJ and associated comorbidities in the population study 
 
Risk factor All patients (No) 
Total 121 
Dental caries 30 
Periodontal disease 
Gengivitis 
Chronic periodontitis 
21 
60 
27 
Poorly fitting dentures 16 
Oral hygiene 
Excellent 
Good 
Fair 
 
0 
22 
30 
Poor 69 
Comorbidities 
Diabetes mellitus 
Rheumatoid arthritis 
Osteoarthritis 
Osteoporosis 
 
88 
6 
51 
20 
 
 
A total of 121 patients (57 women, 64 men) were included in this analysis (PA: n = 78; OB: n = 63). 
108 underwent maneuvers of oral health (included Dental hygiene) , 13 patients carried total (upper and lower) mobile 
denture, 64 partial denture. Most subjects had poor oral health, with widespread periodontal disease, gingival 
inflammation, bacterial plaque and in some cases, decayed teeth and halitosis with deep pain radiated to the 
surroundings to the lesion. For this, it was necessary to performe invasive procedures: dental hygiene, scaling and root-
planning, tooth extraction and root canal treatment after antibiotic therapy .  
 
None of the patients in group PA developed BRONJ in the following 18 months. Dental extractions were done for 26 of 
these patients, 72 dental hygiene, 23 scaling and root planing and 8 root canal treatment. 
 
In group OB 36 patients had dental cure: via random selection 16 patients underwent tooth extraction and 16 underwent 
to root canal treatment, with rubber dam and fang; in elements with chronic periodontal disease, after root canal 
treatment, was made de-crowning of the specific element with less discomfort to the patient. 
Before we performed tooth extraction these 16 patients stopped chemotherapy and BP for 15 days  and they started a 
antibiotic therapy for 2 weeks. In these patients we observed BRONJ in 9 cases, 56.2% (9/16). 
 
We describe one case of BRONJ reported OB (Case 1) and one case without BRONJ safe by root canal treatment(Case 
2). 
 
Case 1: female patient, aged 51, stage IV breast cancer treated with chemotherapy and bisphosphonate since June 2009, 
came to our observation with a partial edentulism in the lower jaw, widespread periodontitis and apical lesion at the 
element 44 and distal caries at the element 45 without pain; severe periodontitis with probing 7 at the elements 13 and 
23, only elements of support for removable partial denture (Picture 1.0). The latter caused pain to the patient and 
therefore we opted for extraction therapy after antibiotic prophylaxis and discontinuation of bisphosphonates in the two 
weeks prior to the intervention and then to be rehabilitated with complete dentures. We have performed the extraction 
of the elements 13 and 23 after incision with full thickness periodontal epithelium with detachment for total coverage of 
dental alveolus (healing by first intention) for greater comfort for the patient postoperatively. She has performed with 
mouthwash rinse with chlorhexidine 0.2% and antibiotic therapy for 4 days after surgery. At a control after a week, the 
healing process was under way. The patient was referred to a control at a month, where it was detected a delay in 
healing was therefore programmed to a further control two months from baseline visit. In this occasion, we found 
mucositis and gingivitis in the post-extraction, jaw pain, exposed bone and halitosis. Radiography showed irregular and 
sclerotic bone in the area. Biopsy was performed and histological examination deposed for ONJ. Currently the patient 
after surgical treatment of sequestrectomy partial maxilla in the area affected by ONJ, it is completely healed (Picture 
1.1). 
 
Picture 1.1                                                                 Picture1.0 
 
 
 
 
  
 
 
Case 2: female patient, aged 57, stage IV breast cancer treated with chemotherapy from 2006, with the addition of 
bisphosphonates in 2007; at baseline examination widespread gingivitis and periodontal disease in all teeth with deep 
caries, some which also subgingival (Picture 2.0). 
The patient complained of pain in the upper and lower jaw, so we opted for endodontic therapy after antibiotic 
prophylaxis. It was made the root canal of the elements following the insertion of a rubber dam and fang, taking 
particular care to not damage the pericoronal tissues, in several sessions at a distance of 15 days to be easy on the 
patient. Devitalized elements were clogged with gutta-percha hot condensation technique. For the post-endodontic 
controls at a week, radiography showed that the gradual healing process was under way, at the control at one month, 
radiology has been confirmed and at two months healing was almost complete. Even at the current controls was not 
detected any sign of ONJ (Picture 2.1). 
 
Picture 2.0                                                                  Picture 2.1 
                                                                                   
     
 
 
 
6. Discussion  
 
Any discussion of BRONJ is hampered somewhat by how little we know of the disease. As noted in the literature 
review, whilst it is accepted that the intravenously administered, higher potency nitrogen containing bisphosphonates, 
usually given for malignant disease are associated with a higher incidence of BRONJ (25), the precise aetiological 
mechanism by which the disease develops has yet to be determined.  
The profound inhibition of osteoclastic activity would appear to be the most visible and possibly therefore, the most 
likely cause. However, we would then expect other medications with similar physiological activity to also predispose 
patients to developing ostoeonecrosis. There have been few cases reported of disease processes similar to BRONJ, 
without the actual influence of bisphosphonates, however isolated incidents have occurred. Recently, osteonecrosis of 
the jaw associated with the use of Bevacizumab were reported. Bevacizumab is a recombinant, humanized monoclonal 
antibody that binds to VEGF, inhibiting angiogenesis, a process that the authors speculate may have predisposed the 
cited patients to osteonecrosis in a similar fashion to which the anti-angiogenic effects of bisphosphonates may 
predispose to BRONJ (60,61). It can also be noted that monoclonal antibodies targeting osteoclastic function, such as 
Denosumab are also undergoing clinical trials (62). There is only a currently study reported cases in the literature of 
Denosumab related osteonecrosis (63). It will be interesting to see more studies about Bevacizumab-related 
osteonecrosis develop, or if Densumab patients subsequently develop osteonecrosis, and what influence this may have 
on our understanding of BRONJ. 
 
In this study, all patients received BP because they had oncological diseases. Although the mechanism of BRONJ is still 
not clear, many reports ascribe a causative role to therapy with BP (64). An hypothesis is that BP-associated BRONJ is 
probably due to a complex interplay of suppressed bone remodeling and hypovascularity compounded by local trauma, 
to an alteration in the normal bone homeostasis process that repairs the physiologic microdamage and to an 
antiangiogenic effects of BP, causing ischemic changes together with microtraumas, inflammations and chronic 
infections (35,17).  
  
The cumulative incidence of BRONJ in patients receiving BPs for malignant disease ranges from 0.8% to 12.0%.(25) In 
the current study, 9 (14,2%) of 63 patients in group OB developed BRONJ patients with bone metastases from different 
solid tumors not previously exposed to a preventive dental examination, who received zoledronic acid and 
chemotherapy combined with the antiangiogenic agent Bevacizumab. 
None of the patients in group PA developed BRONJ, in contrast to the findings of previous studies.(65,26). 
A point to consider is that all these 9 patients required a dental extraction during antitumoral therapy while no ONJ was 
observed in the other patients who received other dental procedures. In these 9 patients the length of i.v. bisphosphonate 
therapy was not longer compared to the other analysed patients (9,13 and 14 months) (66). 
Length of exposure seems to be an important risk factor for this complication. Similarly, in a study from 
Germany,(65)the median time of exposure for patients with ONJ was higher than that for patients without ONJ (32 
months versus 27 months). 
The incidence of ONJ increased with time to exposure from 1.5% among patients treated for 4 to 12 months to 7.7% for 
treatment of 37 to 48 months 
 
Moreover, studies suggest that the incidence of ONJ is related to the type of BP used (24). In the current study, all 
patients with BRONJ received zoledronate therapy. As suggested by the American 
Society of Clinical Oncology, zoledronate is one of the most powerful inhibitors of bone resorption within the drug 
class of BPs and its potency is the basis for the high incidence of BRONJ.(67) 
 
Therefore, with the limits of a retrospective analysis and a small sample size, this study suggests that dental extraction 
during treatment is a particularly precipitating factor in the development in BRONJ in patients receiving chemotherapy 
combined with bevacizumab and BP. (27) Marx et al. first reported of an association between root canal therapy and 
BRONJ in 2005 (68). They observed that 11% of their patients with BRONJ had a history of endodontic treatment, but 
the authors noted BRONJ on teeth with radiographic evidence of failed root canal therapy or an inadequate obturation. 
Hence, there is a caveat to the association with BRONJ, namely the quality of endodontic care. Indeed, the authors of 
the follow-up study suggested that root canal therapy may be a preventive modality for BRONJ development (28). 
Other authors identified dental extractions and treatment with zoledronic acid as significant factors associated with 
development of BRONJ. Precipitating factors there are dental extractions (55%), dental implants (2.9%), periodontal 
disease (41%), trauma related to intubation or poorly fitting dentures (17%), and bone exostosis at the site of 
osteonecrosis (34%). Marx et al. (61) also reported that 37.8% of their patients with BRONJ were associated with dental 
extractions, 29% due to periodontal disease and 11% to periodontal surgery; in another study (111) seventeen patients 
(16%) with Multiple Myeloma treated with BP developed BRONJ after a median number of 43 BP infusions. In 11 of 
17 patients, BRONJ arose after a tooth extraction. There is a risk of spontaneous ONJ occurring in any patient on 
bisphosphonates. Based on Australian data, (65) a dental extraction can increase this risk of BRONJ by a factor of up to 
seven. For the patients who have received bisphosphonates for the treatment of malignancy the risk of post-extraction 
BRONJ is high while for the majority of patients who have received bisphosphonates for the management of 
osteoporosis, the risk of post-extraction BRONJ is lower. Indeed in the cancer patients there is an increasing recognition 
of the influence of other risk factors in relation to post-extraction BRONJ, the concurrent prescribing of 
chemotherapeutic agents with corticosteroids and bisphosphonates place the patient at a higher risk of spontaneous and 
post-extraction BRONJ (71). 
Our data confirm the importance of dental extraction as a risk factor of BRONJ and report that 56,2% (9/16) (72) of our 
patients with BRONJ are associated with dental extractions under antibiotic therapy, in addition this patients received 
antiangiogenic therapy with Bevacizumab, another important risk factor for the development of BRONJ. 
 
The study of Hoff et al (73) confirmed and highlighted observations made by others regarding the relationship between 
preexisting dental health and development of BRONJ. These findings further reinforce the recommendation for pre-BP 
dental evaluation as a strategy for prevention of BRONJ. In addition, caution should be exercised in performing dental 
extraction in patients receiving intravenous BP treatment as part of a cancer therapy regimen (73). In this setting, an our 
previous study suggested that a dental examination and preventive dental measures can minimize the risk of developing 
ONJ, but not that is safe to provide dental care when patients are receiving zoledronic and bevacizumab therapy. In this 
previous study all dental extractions, if needed, were performed before starting antitumoral treatment while in the 
current study all patients had already started when BP and bevacizumab and a preventive dental examination had not 
been performed. It is interesting that the 16 patients with root canal treatment have not developed ONJ, suggesting that 
a mini invasive procedure may be safely reccomended for patients who have already started zoledronic acid + 
bevacizumab, while tooth extraction remains as one of the most important risk factors for the development of BRONJ in 
this type of patients. It is increasingly recognised that the healing ability of the oral soft tissues in these cases appears 
also to be compromised, the exact nature of which has not yet been established. When extractions are performed, the 
ensuing breach in the protective soft tissue envelope leads to long-term jaw exposure and secondary infective 
complications. The insidious, progressive osteomyelitis that often follows can be very destructive (71). Extraction 
avoidance strategies and adjunctive therapy may reduce or delay this disease process. A wide spectrum of jaw disease 
and risk of BRONJ therefore exists, but unfortunately reliable tests or markers for assessing the healing ability of the 
oral soft tissues and the underlying bone are not yet available. 
 
The preventive strategies adopted for this study may have been effective and reduced the risk of 
osteonecrosis. Indeed, data from another our study (61) indicate that preventive dental treatment decreased the risk of 
BRONJ among patients with malignancy treated with BP. 
 
7. Conclusion 
 
The stated aim of this project was to review the pathogenetic hypothesis and new preventive measures on the use of 
bisphosphonates, in a general population attending a public dental care facility. 
 
The BRONJ lesions were treated with antibiotic therapy in all patients and two patients also received hyperbaric oxygen 
therapy. 
Some patients were pre-treated with antibiotic therapy (Azithromicin 500 mg/day) for 10 days prior to the initiation of 
the medical O3 (ozone therapy) oil treatment (57). In addition to antibiotic treatment, the exposed bone and 
osteomucosal edge were cleaned with a tartar supersonic scaler in order to reduce the infective component at gum level 
and favour the penetration of O3 oil through the mucosa around the ONJ lesion. We applied the O3 oil suspension in 
situ, directly on the ONJ lesion area using a patient customised silicone device. 
Propellant clinical response was achieved in all patients treated.  
 
 
Our main theory that BRONJ is a form of avascular necrosis similar to osteoradio-necrosis also has been proposed. It 
maybe hypothesized that the combination of the antiangiogenic agent bevacizumab (BEV) with ZOL can lead to the 
enhancement of bone tissue avascularization, which can account for a potentially higher incidence of BRONJ in patients 
with metastases to the bone who receive this type of treatment. 
 
About new preventive measures we support the safety of root canal therapy in patients receiving bisphosphonates, it 
may be employed as a risk reduction strategy, as it may be used to delay or avoid dental extractions (1,69); in 
conclusion our study suggests that the incidence of ONJ in patients receiving BP and bevacizumab who requires dental 
extraction during treatment may be much higher compared to that usually reported, although further research is needed 
to elucidate the complex interactions of BP with chemotherapy and with antiangiogenic therapies; current evidence 
suggests that root canal therapy in these patients is a safe procedure and may well reduce the prevalence of BRONJ (74) 
 
Although the incidence of BRONJ is fairly low, it remains a painful and difficult complication to treat. An 
interdisciplinary approach involving dentists, medical oncologists, oral and maxillofacial surgeons, and others is a good 
strategy to prevent and manage this condition. Also, a preventive regimen involving the maintenance of good oral 
hygiene should be emphasized.  
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Abstract 
Background. The aim of this paper was to evaluate the activity and tolerability of docetaxel (D) and 
bevacizumab (Bev) in patients with metastatic castrate-resistant prostate cancer (CRPC) previously exposed 
to D. Methods. Treatment consisted of D 30 mg/m2 i.v. for four consecutive weekly administrations followed 
by a 2-week rest interval, in addition to Bev 5 mg/kg i.v. every 2 weeks. Results. Forty-three patients were 
enrolled: a PSA response was observed in 27 patients (62.7%, 95% CI: 0.41 to 0.91), and a palliative 
response was achieved in 31 patients (72.1%, 95%CI: 0.48 to 1.02). After a median followup of 11.3 months, 
only five patients had died. The regimen was generally well tolerated. Conclusion. Weekly D + biweekly Bev 
seems to be an effective and well-tolerated treatment option for patients with metastatic CRPC previously 
exposed to D-based chemotherapy. 
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1. Introduction 
The results of two large randomised trials have provided substantial support in favor of the role of 
chemotherapy in the treatment of castrate-resistant prostate cancer (CRPC) by demonstrating that docetaxel 
(D) and prednisone (P) improve survival in comparison with older regimens and significantly improve the 
quality of life [1, 2]. Therefore, D has become the first-line standard of care for metastatic CRPC, with PSA 
responses of about 50% and median survivals of usually less than 20 months. 
Patients with CRPC who progress after D treatment may be considered for a second-line chemotherapy, 
especially if they have a reasonable performance status, have symptoms, and/or are likely to soon develop 
symptoms for their disease. In this setting, a recent randomized phase III trial demonstrated that cabazitaxel, 
a tubuline-binding taxane drug, improved survival in metastatic CRPC patients with progressive disease after 
D-treatment, with a 30% reduction in the risk of death compared with mitoxantrone taken as control group 
[3]. 
D resistance is a common problem in the treatment of many tumors including CRPC, and the development of 
new drugs that may overcome such resistance is important to extend D activity [4]. 
Angiogenesis is an important process for growth, progression, and metastasis of solid tumors, and the 
inhibitor of the vascular endothelial growth factor (VEGF) bevacizumab (Bev) is currently approved for the 
treatment of colon, lung, breast, and clear cell renal carcinoma in the metastatic setting [5]. 
In addition, preclinical data demonstrated that VEGF inhibition may also prevent further tumor growth of the 
prostate cancer cell line DU 145 implanted in nude mice, and preliminary clinical studies suggested that Bev 
combined with chemotherapy is tolerable and has promising activity in CRPC patients [6, 7]. 
Although Bev achieved no PSA response when it was used in monotherapy, interesting results were 
reported by the combination of Bev with D and estramustine as first-line treatment in a previous study of the 
Cancer and Leukemia Group B [8]. Moreover, a recent study described promising data in terms of PSA 
response and objective response in pretreated patients with CRPC receiving D and Bev [9]. On these 
previous experiences, and in the hypothesis that Bev may overcome the resistance to D, we tested the 
activity and tolerability of Bev combined with D in CRPC patients with disease progression during or after D-
based first-line chemotherapy. 
  Other Sections▼ 
2. Patients and Methods 
2.1. Eligibility Criteria 
This phase II study involved patients with histologically confirmed, measurable, or evaluable advanced 
prostatic adenocarcinoma who had progressed while on D or within 60 days after the last D dose. This last 
eligibility criterium, together with a minimum of 3 months of D-based chemotherapy as first-line treatment, 
was required in order to better elucidate the benefit of the addition of Bev. Patients were admitted to the 
chemotherapy protocol provided that they met at least one of the following criteria: a positive bone scan a 
≥25% increase in PSA (PSA higher than 2 ng/mL) in comparison with baseline on two successive occasions 
separated by at least two weeks for patients without measurable disease; new metastatic lesions revealed 
by a bone scan; and a ≥25% increase in a bidimensionally measurable tumor mass. All of the patients had to 
have an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of ≤ 2, adequate 
hematological (leukocytes ≥ 3000/mm3; hemoglobin ≥ 10 g/dL, platelets ≥ 100,000/mm3), renal (serum 
creatinine ≤ 2.0 mg/dL), and hepatic function (serum bilirubin ≤2.0 mg/dL; Table 1). 
 
Table 1 
Main eligibility criteria. 
Patients were excluded if they had not received prior D-based chemotherapy or if they had congestive heart 
failure, a recent myocardial infarction, or any other previous malignant diseases except basal cell carcinoma 
of the skin. Bisphosphonates were admitted in all of patients who presented with bone metastases. 
The study was approved by the ethical committee of Siena University, and all patients provided their written 
informed consent. 
2.2. Treatment Plan 
Treatment consisted of D 30 mg/m2 as a 30-minute intravenous infusion, using a schedule of four 
consecutive weekly administrations followed by a 2-week rest interval, in addition to Bev 5 mg/kg 
intravenously every 2 weeks. Premedication consisted of P 10 mg p.o. (12 h before, at the time of, and 12 h 
after D administration). Cycles were administered if serum leukocytes were ≥3000/mm3, granulocytes > 
1500/mm3, and platelets > 100,000/mm3. Ondansetron 8 mg was administered at the beginning of each 
treatment cycle as antiemetic medication. The patients continued to take analgesic medication at doses 
adjusted to provide optimal pain control. The chemotherapy was administered until disease progression or 
unacceptable toxicity, and for a maximum of 30 weekly D cycles. In responding patients, Bev could be 
continued at the investigator's discretion, or until disease progression or unacceptable toxicity. 
2.3. Response Assessments 
Tumor response in patients with measurable lesions was evaluated using the RECIST criteria [10]. Serum 
PSA was measured every three weeks: a PSA response was defined as a reduction from baseline of at least 
50% for at least three weeks whereas PSA progression was defined as an increase from nadir of at least 
25% and ≥2 ng/mL [11]. Pain symptomatology was measured at baseline and then every 6 weeks by the 
McGill Melzack Pain Questionnaire, and pain response was defined as a 2-point reduction in the 6-point 
present pain intensity scale (or the complete disappearance of pain if the initial score was 1+) [12]. These 
results had to be maintained at two consecutive evaluations made at least 3 weeks apart and without any 
increase in analgesic consumption. The patients were asked to classify the average pain level during the 
previous 24 h. We used a translated form of the McGill Melzack Questionnaire to which the “reconstruction-
based methodology” has been applied [13]. Analgesic consumption was based on the average daily 
quantities taken by the patient during the previous week, and assigned oral morphine equivalents before 
analysis [14]. 
The laboratory studies (blood and platelet counts, and a comprehensive screening profile) were performed at 
baseline and every three weeks, and the patients underwent a weekly complete blood cell count and 
electrolytes profile before chemotherapy. 
The imaging studies included abdominal and pelvic CT or magnetic resonance imaging, a bone scan, and 
chest radiography. All measurable diseases were reevaluated at 8-week intervals. Radionuclide bone scans 
were repeated after 3 months. In all subjects, fasting venous blood samples were drawn between 8.00 and 
9.00 a.m. after a 12-h fasting period at baseline and after 3 months in order to assess the bone resorption 
marker crosslinked C-terminal telopeptide (CTX) and the bone formation marker bone alkaline phosphatase 
(B-ALP). 
In all cases, a baseline ECG was obtained, and a further cardiac work-up was performed if indicated. Bone 
disease progression was defined as the appearance of any new bone lesion or the progression of existing 
bone metastases. A dental examination, including orthopantomography (OPT), was performed in all patients 
at baseline, and active dental surveillance every three months. 
2.4. Treatment-Related Adverse Events 
Toxicity was defined using the National Cancer Institute (NCI) Common Toxicity Criteria, version 3.0. The 
treatment was delayed at the first occurrence of grade II hematological toxicity, and administered at the 
same dose after it returned to grade I or better. In the case of grade III or IV toxicity, the treatment was 
interrupted and a maximum of three weeks was allowed for recovery, after which the patients were 
withdrawn from the study. In the case of a second episode of grade III or IV toxicity in the same patient, 
treatment was resumed after recovery and the subsequent administration of D was reduced to 20 mg/m2. 
Chemotherapy protocol was discontinued if the ejection fraction decreased below the institutional lower limit 
of normal and declined by ≥15%. 
2.5. Statistical Considerations 
The primary endpoint was PSA response. In accordance with Simon's “optimal design”, a sample size of 36 
patients was planned, assuming a response rate of approximately 10% for other second-line 
chemotherapies, and a target level of interest of 30%, with an α of 0.05 and a β of 0.90. In the hypothesis of 
10%–20% inevaluable patients, about 40 patients were planned to be enrolled to better estimate the 
response. Secondary endpoints were pain response, progression-free survival (PFS), and overall survival. 
PFS was defined as the time from starting chemotherapy to the first occurrence of objective or PSA 
progression, or death due to any cause. 
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3. Results 
From September 2008 to April 2010, 43 patients were enrolled. Their median age was 74 years (range 58–
82 years) Thirty-seven patients had bone metastases. and seventeen patients had measurable disease 
(Table 1). Most of enrolled patients have participated in a randomized phase II study which compared the 
combination of weekly D and weekly Epirubicin (EPI) with the conventional 3-weekly D [15]. All patients who 
had achieved a response or a stable disease during first-line chemotherapy had been retreated with D-based 
chemotherapy. The median dose of D received before the enrollment in the current study was 940.8
mg/m2 (range 30–1122,3). 
All enrolled patients were treated with the new treatment regimen within 60 days from the end of last D dose 
(range 12 to 52 days). Two patients received only one weekly chemotherapy cycle for treatment-unrelated 
reasons. Two patients were lost to followup after four and six months from the start of treatment. All patients 
were included in the overall analysis (intent-to-treat). A total of 968 weekly D cycles (median 21, range 11–
30) and a total of 1172 biweekly cycles of Bev (median 26, range 6–41) were administered. 
3.1. Biochemical Response 
A decrease in PSA levels >50% was observed in 27 patients (62.7%, 95% CI: 0.41 to 0.91), and nine 
patients (20.9%) had stable PSA for at least twelve weeks (Table 3). After the first 3 weekly cycles a PSA 
surge was observed in 18 out of 27 responding patients: in all these patients PSA then progressively 
decreased and at the third month was less than 50% with respect to the baseline values (Figure 1). 
 
Table 3 
Response to treatment. 
 
 
 
Figure 1 
Median PSA (with minimum and maximum values) in 
18 out of 27 responding patients who showed a PSA 
surge within the first 3 months of treatment with weekly 
D + biweekly Bev. 
During the prior first-line chemotherapy, 15 out of the 27 responding patients had achieved PSA response 
while 8 had achieved stable disease and 4 patients had progressed. 
3.2. Objective Response 
Of seventeen patients with measurable disease, eight achieved PR and seven had stable disease: objective 
responses were observed on prostate cancer (3 cases), prostate cancer and pelvic lymph nodes (3 cases), 
and prostate cancer and lung metastases (2 cases). 
The bone scan, which could be repeated after 3 months of treatment in 35 out of 37 patients with bone 
metastases, showed stable disease in 29 patients, and partial remission in 5 patients; two or more new 
lesions compared with the prior scan for trial entry were described in one patient. This same patient had PSA 
progression after 3 months and chemotherapy was stopped. The bone markers CTX and B-ALP were 
reduced >50% with respect to baseline values in 33 and 28 patients, respectively, after 12 weeks from the 
start of treatment (65% median reduction for CTX and 58% median reduction for B-ALP). A palliative 
response was observed in 31 patients after 12 weeks (72.1%, 95% CI: to 0.48 to 1.02). 
After 12 weeks from the start of the new treatment protocol, seven patients (including two subjects who 
received only one treatment cycle) had PSA progression, but three of them had a reduction in bone pain with 
decrease in analgesics use, improvement in performance status, and reduction in serum levels of the bone 
markers CTX and BALP. Despite the initial end-point of the study, because of the achieved clinical benefit, 
our oncology group and the scientific ethical committee decided to continue D + Bev in these three patients 
until worsening of pain and/or performance status. 
After a median followup of 11.3 months, 18 patients showed PSA progression and only five patients had 
died. 
The regimen was generally well tolerated, and no unexpected toxic effects were observed (Table 4). No 
grade 4 toxicity or congestive heart failure was observed, and all cycles were administered on an outpatient 
basis. The most frequent side effects were neutropenia, anemia, thrombocytopenia, epistaxis, and fatigue, 
which were grade I or II in most cases. Grade III fatigue was observed in two patients after nine and sixteen 
cycles, respectively: despite the reduction of D dose and the discontinuation of Bev, treatment was then 
interrupted in these cases because of the persistence of this side effect. Grade 1 epistaxis was observed in 
23 patients (53.4%) during treatment, but reached grade 2 in only 7 cases and grade 3 in one patient. No 
patient developed osteonecrosis of the jaw (ONJ). Dose reduction of D was required in a total of twelve 
patients: 37 (3.8%) weekly D cycles were administered with a 33% reduction, down to 20 mg weekly. A total 
of 57 (5.8%) weekly D cycles were delayed: the reason for the delays were hematological in 41 (71.9%) and 
nonhematological in 16 (28.1%) cycles. A total of 46 (39.2%) biweekly Bev cycles were delayed: the reasons 
for the delays were haematological in 39 (84.8%) and non-hematological in 7 (15.2%) cycles. 
 
Table 4 
Number of patients experiencing the most frequent 
treatment-related adverse events. 
  Other Sections▼ 
4. Discussion 
The currents phase II study is the first extended report which suggests that the combination of weekly D with 
the biweekly administration of the antiangiogenic agent Bev is effective and tolerable in the treatment of 
patients with metastatic CRPC who have progressed after D-based chemotherapy: the 62.7% PSA and 
72.1% palliative response compare favorably with the results observed in phase II studies of second-line 
chemotherapy [16, 17]. Other chemotherapeutic agents might be used after initial treatment with D, including 
old drugs such as vinorelbine, oral cyclophosphamide, etoposide, mitoxantrone, vinblastine, and doxorubicin, 
but most studies reported no objective response and less than 15% laboratory response [18]. Other studies 
described modest activity with satraplatin, a third-generation platinum analog, or ixabepilone, an epothilone, 
with mitoxantrone, or also with the combination of D and high-dose calcitriol [19–21]. 
It must be remembered that in most clinical trials a few patients stop the first-line treatment with D while still 
responding to the drug. In this group of patients a repeated treatment with D might be appropriated if 
progression occurs after a reasonably long time interval [22]. In our study, the strict eligibility requirement of 
progression while on D or within 60 days of the last D dose means that these patients might have not 
responded to rechallenge with D. Notably, responses were seen also in patients who had not shown an initial 
response to prior D as first-line treatment. Therefore, this finding and the characteristics of enrolled patients 
support an effective role of Bev in restoring the sensitivity to D and also in reversing resistance in patients 
who were previously nonresponders to the drug (Table 1). Bev is able to alter tumor vasculature, for 
example, decreasing tumor vessel permeability and increasing intratumoral perfusion, which might turn into 
an improved tumor delivery of a cytotoxic agent, thus enhancing its antitumor activity [23]. Since the limited 
tissue penetration is an important mechanism of tumor resistance to taxanes, the effects of the 
antiangiogenic agent Bev may be a possible explanation of the observed reversal of D resistance in our 
population study [24]. 
Another point to consider is the observed PSA surges during treatment protocol in 18 out of 27 responding 
patients, which may suggest massive cancer cell death and PSA release, thus indicating efficacy, as also 
reported in other previous trials during chemotherapy for CRPC [25, 26]. Nevertheless, despite the unknown 
biological relevance of this transient initial PSA increase, most of our patients achieved an improvement in 
bone symptomatology and in performance status, and PSA decreased > 50% at 3 months (Figure 1). 
Furthermore, PSA results correlated with changes in bone markers, since CTX and B-ALP were reduced 
with respect to baseline values in all these patients, and this was probably related to the real antitumor 
activity of the D + Bev combination. 
Notably, despite PSA progression after 3 months of treatment, three patients continued to have an 
improvement in performance status and reduction in bone symptomatology and bone markers, and because 
of this achieved clinical benefit they continued to receive D + Bev. This finding may confirm that the 
progression criteria that are usually suitable for assessment of efficacy of cytotoxic agents in CRPC may not 
be suitable for discriminating treatment effects of targeted agents such as Bev [27, 28]. It may be that 
significant treatment benefits with targeted therapies need long time scales to emerge, possibly due to its 
noncytotoxic-targeted mechanism of action. 
As Bev-based salvage treatment, a 55% PSA response and 37.5% objective response was found in 20 
pretreated patients with CRPC receiving D 60 mg/m2 and Bev 10 mg/kg every 3 weeks [9]. Another recent 
experience suggested a benefit in progression-free and in overall survival by the use of weekly D 25
mg/m2 combined with Bev 10 mg/kg every two weeks in CRPC patients [29]. The toxicity profile of our 
treatment protocol was comparable to that observed in these BEV-based salvage treatments, with a major 
incidence of grade IV neutropenia and thrombocytopenia reported by the use of 3-weekly D schedule. 
Considering the strict eligibility criteria of our study and the fact that all our patients had previously received 
at least two chemotherapy lines, the current results appear even more encouraging than that found in the 
aforementioned reports. Nevertheless, it must be considered that most of metastatic CRPC patients who 
relapse after the first line D and D rechallenge do not survive more than 6 months. It is notable that in the 
current study, after a median follow-up time of 11.3 months, only five patients had died and most patients 
who started the new treatment protocol more that 12 months ago are still alive and have a good quality of 
life. 
Therefore, although three-weekly D and P remains the conventional treatment protocol in first-line setting, it 
may be hypothesized that weekly D combined with biweekly Bev, as applied by us, is an appropriate 
schedule in terms of activity and toxicity for heavily pretreated patients. The combination of weekly 
scheduling of D with Bev has shown interesting activity without significant toxicity also in breast, ovarian and 
mesenchymal tumors [30–32]. 
The efficacy and safety results of the current study compare favorably also with those reported with the drug 
cabazitaxel, that was recently approved by US Food and Drug administration for second-line treatment of 
metastatic CRPC patients [3]. Severe neutropenia was common in cabazitaxel trial (89%), and 18% of 
patients discontinued the study treatment because of adverse events while grade III neutropenia was 
observed in only 18.6% of cases in our population study. Nevertheless toxicity was mild in our patients: 
adverse events likely related to Bev (hypertension, epistaxis, and albuminuria) never reached grade 3 and 
were easily manageable, as usually reported in other tumors with the biweekly schedule of 5 mg/kg of Bev. 
The low toxicity of D was mainly due to the weekly schedule. The efficacy of weekly D seems to be similar to 
that of the usual 3-weekly schedule, but their comparative toxicities differ markedly, with moderate to severe 
myelosuppression being common when the drug is administered once every 3 weeks [33]. As well as is 
concerned other adverse events, Altough the new and potent antiangiogenic therapies might theoretically 
enhance the antiangiogenic effects of zoledronic acid on bone tissue, our findings do not suggest a trend for 
a possible higher incidence of bisphosphonate-induced ONJ for patients receiving zoledronic acid and Bev 
[34]. 
Another point to consider is that the percentage of enrolled patients ≥75 years was about 50% in the current 
study, compared with only 18% in cabazitaxel trial. On these findings, it seems that weekly D and biweekly 
Bev can be safety administered also to elderly patients, who represent the most part of CRPC population. 
Therefore, although cabazitaxel will be the only established second-line treatment of CRPC patients in the 
next future, weekly D and Bev may be a valid option for patients with a decreased hematological reserve 
and/or for elderly subjects. Moreover, in the absence of a randomized comparison between cabazitaxel and 
our proposed treatment protocol, weekly D and Bev might be used after cabazitaxel failure. 
In conclusion the results of this study suggest that weekly D and biweekly Bev is an effective and well-
tolerated treatment option for patients with metastatic CRPC previously exposed to D. Bev seems to 
overcome the resistance to the drug in patients who had progressed during or after D-based chemotherapy. 
5. Conclusion 
Weekly D + biweekly Bev seems to be an effective and well-tolerated treatment option for patients with 
metastatic CRPC previously exposed to D-based chemotherapy. 
 
 
Table 2 
Main patient characteristics. 
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Abstract  
Background    
The aim of this study was to assess the early effects of zoledronic acid (ZOL) and oral ibandronate 
(IBA) on the bone resorption marker s-CTX (serum C-telopeptide of collagen type I) and the bone 
formation marker B-ALP (bone-alkaline phosphatase) in patients with bone metastases from non-
small cell lung cancer (NSCLC).  
Methods    
Fifty-five patients with at least one site of bone metastasis secondary to NSCLC were randomly 
assigned to receive intravenous ZOL 4 mg every 4 weeks, or oral IBA 50 mg/day.  
Results    
At 1 month of treatment, s-CTX was reduced by 54.8% (95% CI 40.4–59.8%) in the ZOL group (26 
evaluable patients) compared with 38.2% (95% CI 29.8–48.7%) in the oral IBA group (27 
evaluable patients) (p = 0.03). At 3 months, s-CTX was reduced by 72.6% (95% CI 58.6–71.3%) in 
the ZOL group, compared with 66.4% (95% CI 54.3–79.5%) in the oral IBA group (p = 0.22). Both 
bisphosphonates similarly decreased the bone marker B-ALP at 1 month (ZOL 24.7%, 95% CI 3.6–
39.5%, and IBA 24.2%, 95% CI 2.8–43.4%) and 3 months (ZOL 28.6%, 95% CI +2.8–43.3%, and 
IBA 24.2%, 95% CI 3.2–47.4%). Both bisphosphonates were well tolerated.  
Conclusion    
Considering the changes in bone markers, ZOL and oral IBA show comparable efficacy in patients 
with NSCLC and bone metastases. 
Keywords  Bone markers – Bone metastases – Breast cancer – Ibandronate – NSCLC – Prostate 
cancer – Zoledronate  
 
Introduction 
Bone is a frequent site of metastasis in patients with many solid tumors, including non-small cell 
lung cancer (NSCLC) [1]. Metastatic bone disease is associated with the potential occurrence of 
skeletal-related events (SREs), including pathologic fractures, spinal cord compression, need for 
radiation and/or surgery to bone, and hypercalcemia, which can cause severe morbidity and 
reduction in quality of life [2]. Bisphosphonates are drugs that effectively inhibit bone resorption 
and are now recommended as an important component of care to prevent skeletal complications in 
patients with bone metastases.  
Zoledronic acid (ZOL) and ibandronate (IBA) are the two newer aminobisphosphonates with 
substantial activity and tolerability for the treatment of metastatic bone disease [3, 4]. ZOL 
demonstrated high efficacy in the treatment of hypercalcemia of malignancy (HCM) and bone 
metastases from different solid tumors [5, 6]. IBA reduced the risk of new SREs by approximately 
40% in patients with breast cancer and bone metastases in placebo-controlled phase III trials, and 
also exhibited efficacy in patients with bone metastases from a variety of other primary 
malignancies [7, 8]. IBA is available also as an oral formulation, which seems to have an equal 
efficacy to i.v. administration, is well tolerated, exhibits long-term safety, and offers convenient 
home administration [9]. IBA is approved only for the treatment of bone metastases from breast 
cancer, and few data are reported on the use of this bisphosphonate in NSCLC patients with bone 
lesions. Moreover, at the start of the investigation described in this work, there were no data that 
directly compared the activity of ZOL and oral IBA in patients with bone metastases from different 
solid tumors, including NSCLC.  
Although the reduction of SREs is the primary endpoint in patients with bone metastases, the 
measurement of biochemical markers of bone metabolism, which reflect both bone resorption and 
formation, can provide useful information about the effects of bisphosphonates and underlying 
anticancer therapy [10, 11]. A marked reduction in the levels of bone resorption markers during 
treatment with bisphosphonates in cancer patients with bone metastases has been reported, resulting 
in fewer skeletal complications and a more favorable prognosis. The bone resorption markers type I 
collagen telopeptide NTX (serum and urinary concentration) and serum level of crosslinked C-
terminal telopeptide (s-CTX) exhibited similar efficacies for the prediction of SREs in metastatic 
bone disease [12, 13]. One of the most well-investigated bone formation markers, bone alkaline 
phosphatase (B-ALP), was useful for monitoring treatment with bisphosphonates in patients with 
prostate cancer, lung cancer, and other solid tumors [14, 15].  
The aim of this study was to assess the early effects of ZOL and oral IBA on the bone turnover 
markers s-CTX and B-ALP in patients with bone metastases from NSCLC.  
 
Patients and methods 
Patients ≥18 years of age with an Eastern Cooperative Oncology Group (ECOG) performance status 
of ≤2 and at least one site of bone metastasis secondary to NSCLC were eligible. Patients were 
excluded if they had liver metastases with a total bilirubin level of >2.5 mg/dL, a serum creatinine 
level of >3.0 mg/dL, or symptomatic brain metastases. Patients were also excluded if they had been 
previously exposed to bisphosphonates, had severe cardiovascular disease, hypertension refractory 
to treatment, or symptomatic coronary artery disease. The study was approved by the local 
institutional ethical committee, and all patients provided written informed consent.  
In all subjects, fasting venous blood samples were drawn between 8.00 and 9.00 a.m. after a 12-h 
fasting period at baseline and at one and three months in order to assess s-CTX and B-ALP. A 
complete blood chemistry, including serum electrolytes, calcium and magnesium, was performed at 
baseline and then every 3 weeks. Decreased renal function was defined as a change from the 
baseline serum creatinine of ≥0.5 mg/dL for patients with normal baseline serum creatinine and 
≥1.0 mg/dL for patients with abnormal baseline serum creatinine, or at least double the baseline 
values.  
S-CTX was evaluated by an enzyme-linked immunosorbant assay (ELISA) method (Serum Cross 
Laps ELISA, Nordic Bioscience Diagnostics, Herlev, Denmark). The intra- and interassay 
coefficients of variation for s-CTX at our institution were 5.4 and 7.9%, respectively. B-ALP was 
measured by a radioimmunometric method (BALP-Tandem-R Ostase, Hybritech, San Diego, CA, 
USA). The intra- and interassay coefficients of variation for B-ALP in our institution were 6.7 and 
8.1%, respectively.  
The normal ranges of s-CTX and B-ALP were obtained in age-matched groups of 100 healthy 
males and 100 healthy pre- and postmenopausal women.  
All patients had stage IV disease. A radionuclide bone scan and other radiologic techniques (X-ray: 
Rx; computed tomography: CT, and/or magnetic resonance imaging: MRI) were performed at 
baseline and repeated every 6 months. Bone metastasis response was evaluated by the bone-specific 
response criteria of the MD Anderson Cancer Center (MDA), which updated previous bone 
response criteria by expanding radiographic assessment and incorporating both CT and MRI [16]. 
Bone marker data should be available for all patients at baseline and at 1 and 3 months.  
Pain measurement was performed according to the 6-point pain intensity scale of the McGill–
Melzack pain questionnaire at baseline and then after 1 and 3 months [17]. The pain scale has 
verbal descriptors (0, no pain; 1, mild pain; 2, discomforting pain; 3, distressing pain; 4, horrible 
pain; 5, excruciating pain), and the patients were asked to classify the average pain level during the 
previous 24 h. We used a translated form of the McGill–Melzack questionnaire to which the 
“reconstruction-based methodology” was applied [18]. Analgesic consumption was based on the 
average daily quantities taken by the patient during the previous week, and assigned oral morphine 
equivalents before analysis [19].  
Treatment 
Patients were randomly assigned to receive intravenous ZOL 4 mg via 15-min infusion in 100 mL 
every 4 weeks, or oral IBA 50 mg/day. IBA tablets were taken after an overnight fast (at least 6 h) 
and at least 30 min before the first food or drink of the day. Conventional chemotherapy for patients 
with advanced NSCLC was started at the same time as bisphosphonates. Bisphosphonates were 
administered until the occurrence of severe adverse events, and for a maximum of 2 years.  
Before the first study treatment, the medical history was reviewed and a complete physical 
examination, tumor assessment, bone scan, and bone survey were performed. Pain and analgesic 
scores were assessed at baseline and then at 1 and 3 months. A dental assay, performed in order to 
reduce the risk of development of osteonecrosis of the jaw (ONJ), was performed at baseline and 
then every 3 months.  
Tumors were evaluated every 3 months according to the Response Evaluation Criteria in Solid 
Tumors (RECIST) [20]. Skeletal-related events (SRE), including pathologic fracture, spinal cord 
compression, radiation therapy to bone, or surgery to bone, were recorded at each visit every 
4 weeks.  
Statistical analysis 
Assuming about a 70% decrease in s-CTX at 3 months of treatment with ZOL in patients with bone 
metastases, the study required the enrollment of at least 26 patients per treatment group with 90% 
power to detect a 15% difference in the median percentage change in s-CTX between ZOL and oral 
IBA at 3 months of treatment [21]. Secondary end-points were bone pain and the proportion of 
patients with at least a SRE; time to first SRE, time to progression of bone metastases, and overall 
survival were determined using the Kaplan–Meier method, and treatment groups were compared 
using the log-rank test.  
The comparison of the median percentage change from baseline of bone markers during the 
observation period between the two groups was achieved using the Mann–Whitney test. All tests 
were two-sided with a significance level of 0.05.  
 
Results 
From April 2005 to May 2010, 55 patients with NSCLC and bone metastases were enrolled in the 
study and randomly assigned to receive ZOL or oral IBA; 53 received at least 3 months of treatment 
and were considered evaluable (2 patients in the ZOL group received less than 2 months of 
treatment because of reasons unrelated to treatment). The two treatment groups were well balanced 
for age, performance status, pain score, number and type of bone metastases, anticancer therapies, 
and baseline median values of the bone markers s-CTX and B-ALP (Table 1).  
Table 1 Baseline characteristics  
  ZOL IBA 
Enrolled patients 28 27 
Evaluable patients 26 27 
Median age, years (range) 69 (55–79) 71 (62–78) 
Male 22 19 
Female 6 8 
No of bone lesions 
 >3 15 16 
 ≤3 13 11 
 ≥2 Metastatic sites 23 25 
Predominant lytic 26 25 
Predominant blastic 2 2 
SRE before treatment 1 1 
s-CTX (ng/ml) (range) 0.94 (0.18–2.95) 0.91 (0.22–3.16) 
B-ALP (IU/L) (range) 24.8 (8.66–72.12) 32.1 (12.3–89.5) 
Pain score 1.98 ± 1.12 1.88 ± 0.89 
Chemotherapy 
  ZOL IBA 
 CDDP/GEM 14 16 
 CDDP/VBN 4 3 
 CDDP/GEM + BEV 10 8 
S-CTX and B-ALP are expressed as median values, and pain score as mean ± standard deviation (SD) 
CDDP/GEM cisplatin and gemcitabine, CDDP/VBN cisplatin and vinorelbine, BEV bevacizumab  
Of 26 assessable patients in the ZOL group, 18 (69.2%) and 15 (57.6%) had baseline s-CTX and B-
ALP above the normal range, respectively. Of 27 assessable patients in the IBA group, 20 (74.0%) 
and 17 (62.9%) had baseline s-CTX and B-ALP above the normal range, respectively.  
At 1 month of treatment, S-CTX was reduced by 54.8% (95% CI 40.4–59.8%) below the baseline in 
the ZOL group, compared with 38.2% (95% CI 29.8–48.7%) in the oral IBA group (p = 0.03). At 
3 months, CTX was reduced by 72.6% (95% CI 58.6–71.3%) in the ZOL group, compared with 
66.4% (95% CI 54.3–79.5%) in the oral IBA group (p = 0.22) (Fig. 1).  
 
Fig. 1 Median percentage decreases in s-CTX levels with zoledronic acid (ZOL) and oral ibandronate (IBA) 
at 1 and 3 months of treatment  
 
At 3 months, in patients who had elevated baseline s-CTX levels, ZOL and oral IBA normalized the 
bone resorption marker in 84.6 and 77.7% of patients, respectively.  
Both bisphosphonates similarly decreased the bone marker B-ALP at 1 month (ZOL 24.7%, 95% 
CI 3.6–39.5%, and IBA 26.1%, 95% CI 2.8–43.4%) and 3 months (ZOL 28.6%, 95% CI +2.8–
43.3%, and IBA 24.2%, 95% CI 3.2–47.4%) (Fig. 2).  
 
Fig. 2 Median percentage decreases in B-ALP levels with zoledronic acid (ZOL) and oral ibandronate (IBA) 
at 1 and 3 months of treatment  
 
At 3 months, 12 patients (52.1%) in the ZOL group and 14 patients (56.0%) in the IBA group 
showed responses of metastases in parenchymatous organs as evaluated by RECIST criteria. At 
6 months, bone scan and other imaging techniques could be performed in 49 patients, and these 
suggested a partial response of bone lesions in 8 patients (34.7%) in the ZOL group and 10 patients 
(38.4%) in the IBA group.  
All 53 evaluable patients were assessable for pain and analgesic use at 1 and 3 months. At 1 month 
there was a trend for a more rapid decrease in bone pain score in favor of the ZOL group (41.6 vs. 
29.3%; p = 0.05), while the maximum pain relief was achieved at 3 months and was similar in the 
ZOL and IBA groups (66.2 vs. 61.8%; p = 0.31). At 3 months, a decrease in pain score of ≥2 points 
without any increase in analgesic consumption in patients with a baseline pain score ≥2 was 
observed in 11/18 (61.1%) patients in the ZOL group and 9/16 (56.2%) patients in the IBA group.  
There was no significant difference between the two treatment groups in the proportion of patients 
with a new SRE: after a median observation time of 14.5 months, 5 (19.2%) patients in the ZOL 
group and 7 (25.9%) in the IBA group had skeletal complications. The most common SREs were a 
need for radiation to the bone for pain relief and pathologic fracture: the median time to first SRE 
was 10.2 months (range 4.6–14.3) in the ZOL group and 9.4 months (range 5.7–16.1) in the IBA 
group (p = 0.034) (log-rank test).  
Both bisphosphonates were well tolerated. The most common adverse events, considered treatment-
related by the investigators, were bone pain, nausea, constipation, dyspnea, fatigue, and 
gastrointestinal disorders. The incidence of adverse events such as pyrexia and influenza-like 
symptoms in the first 3 days of treatment was higher in the ZOL group than the IBA group (23.0 vs. 
7.4%). One patient in the ZOL group developed ONJ after 15 months of treatment, and one patient 
in the IBA group had to stop taking the drug orally because of gastrointestinal disorders after 
6 months of treatment. The proportion of patients with decreased renal function was slightly higher 
in the ZOL than the IBA group, but the difference was not statistically significant (15.3 vs. 3.7%, 
p = 0.13).  
 Discussion 
This is the first clinical study that compares the early effects of the bisphosphonates ZOL and oral 
IBA on bone resorption in NSCLC patients with bone metastases. A higher initial potency of ZOL 
was suggested by a trend for a more rapid reduction in s-CTX levels and bone pain at 1 month 
compared to oral IBA (p = 0.03; p = 0.05), while at 3 months the effects of the two bisphosphonates 
were comparable (Fig. 1). In addition, a similar high percentage of s-CTX normalization was 
observed with ZOL (84.6%) and oral IBA (77.7%). The early normalization of bone resorption 
markers during treatment is considered an important endpoint, since it has been reported to be 
associated with a reduced risk of first SRE and a significant improvement in survival [22, 23]. With 
the limitation of the small sample size and the short follow-up, ZOL and oral IBA also appeared to 
be comparable in terms of SRE efficacy (19.2 vs. 25.9%). These findings suggest that it may be 
appropriate to start with an intravenous formulation of a potent bisphosphonate (such as ZOL or 
IBA) in patients with widespread and painful bone metastases from NSCLC, while oral IBA seems 
to achieve the same efficacy after 3 months, and thus may also be considered.  
All of the analyzed patients were receiving concomitant chemotherapy, which would be expected to 
influence the s-CTX decrease and changes in bone pain [23, 24]. Nevertheless, the use of a 
concomitant effective first-line chemotherapy achieved overall response rates of 34.7 and 38.4% on 
bone lesions in the ZOL and IBA groups, respectively, which probably contributed to the similar 
clinical activities of the two bisphosphonates observed during treatment. In line with our study, 
recent reports suggested the role of early changes in bone resorption markers for monitoring 
NSCLC patients with bone metastases receiving bisphosphonates combined with chemotherapy [25, 
26].  
Another point to consider is that 10 patients in ZOL group and 8 patients in the IBA group received 
the antiangiogenic bevacizumab (Bev), which is currently approved (in combination with 
chemotherapy) for the first-line treatment of many solid tumors, including NSCLC [27]. Although it 
may be hypothesized that Bev might potentially increase the antiresorptive effects of 
bisphosphonates, the bone resorption marker s-CTX similarly decreased in Bev-treated patients 
compared to patients who were not receiving Bev. However, further studies are needed to clarify 
the impact on bone metabolism of the new antiangiogenic drugs when combined with 
chemotherapy and bisphosphonates.  
The early changes in B-ALP during treatment were similar in the two treatment groups, and a 
substantial proportion of the patients showed a B-ALP increase at 3 months, which was associated 
with a response to treatment in most patients (Fig. 2) In this setting, it must be underlined that while 
a s-CTX increase generally reflects a progression in bone metastases, B-ALP may also increase to 
balance an increase in the osteolytic component, or increase as an indication of bone formation to 
repair bone lesions that respond to treatment [13, 24, 28, 29]. Therefore, the association of B-ALP 
with a response to therapy is usually less consistent than bone resorption markers, since an increase 
in B-ALP may have negative but also positive prognostic implications.  
Our results are similar to those reported in a recent comparative study performed in patients with 
bone metastases from breast cancer, which demonstrated that oral IBA was statistically noninferior 
to ZOL in terms of percentage change in s-CTX at week 12 (76 vs. 73%). The aforementioned 
study suggested that oral IBA also similarly reduced bone pain and bone formation markers at week 
12, while, unlike in our study, early changes in these parameters (i.e., at 1 month) were not 
investigated [30]. Another study reported mean reductions of >40% in the bone markers u-NTX and 
s-CTX in patients with metastatic bone disease treated with daily oral clodronate after 6 weeks of 
treatment [31]. However, a dose–response relationship of oral clodronate was suggested, and the 
commonly used 1,600 mg dose was appropriate for breast cancer patients but suboptimal for other 
cancers. Therefore, in the absence of randomized phase III trials, and considering changes in bone 
marker levels as a surrogate end-point, our results suggest that ZOL and oral IBA administered with 
concomitant chemotherapy have comparable efficacies in NSCLC patients and bone metastases. In 
patients with severe bone pain (who are able to move), widespread bone involvement and high 
baseline levels of bone resorption markers, the current best approach seems to be the administration 
of an effective anticancer treatment combined with i.v. bisphosphonates such as ZOL (or i.v. IBA), 
which achieves a more rapid and potent inhibition of bone resorption. Thereafter, a switch to oral 
IBA, which can be safely used as maintenance therapy for long periods, may be considered. In this 
setting, it is known that patient compliance may be a problem associated with daily oral 
bisphosphonates. Previous randomized trials on osteoporosis reported similar results with oral IBA 
to those seen in our study in terms of reduction in bone turnover markers. However, adherence to 
and persistence with therapy were poor, particularly with daily dosing [32, 33]. It was observed that 
more than half of the patients receiving daily oral bisphosphonates were not compliant and thus 
were at increased risk of fracture compared with compliant patients [32, 34]. However, more 
advanced and convenient oral bisphosphonates schedules are currently available, such as weekly 
and monthly administration [35]. In the current study, all patients were informed about the 
importance of adhering to the treatment, and compliance with oral IBA was good, with 98% of 
patients receiving >90% of the study drug. Both ZOL and oral IBA were well tolerated, and, as 
observed in other studies, the overall incidence of adverse events was lower for patients receiving 
IBA, particularly as for pyrexia and flu-like symptoms on days 1–3 (3.0 vs. 26.8%), while a trend 
for an increase in serum creatinine level was found in the ZOL group [36]. The lack of renal 
toxicity for oral IBA may be an advantage for patients receiving concomitant potentially 
nephrotoxic treatments, and/or for old patients with chronic renal failure in particular, for whom a 
switch to or the initial use of this drug should be considered. Other adverse events were rare, with 
the exception of a case of ONJ which occurred in the ZOL group and required the discontinuation 
of bisphosphonate treatment. In this setting, it should be underlined that all patients receiving ZOL 
should have an oral examination at least every 3 months, while this diagnostic procedure may be 
sufficient at each 6-monthly visit along with oral IBA. Although gastrointestinal toxicity may occur 
with oral IBA, only one subject withdrew from the treatment after 6 months due to severe 
gastrointestinal disorders attributed to this drug by investigators, probably due to the fact that all of 
the patients were well informed and followed the precautionary measures.  
In conclusion, this study may add useful information about the effects of ZOL and oral IBA on 
NSCLC patients with bone metastases, and might help physicians to prescribe the most appropriate 
bisphosphonate based on factors such as safety and convenience. However, the sample size in this 
study was very small, and the observation period for the primary end-point was only 3 months, so it 
is difficult to draw definite conclusions about the most efficacious administration route for 
bisphosphonates (oral or intravenous) in the treatment of bone metastases. A longer observation 
period and an increased number of participants are needed to conclusively demonstrate the effects 
of the treatment on quality of life, continuity of reduction in bone markers, and overall survival.  
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